Near-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing
more »
- Bahcesehir University, Istanbul (Turkey); SLAC
- Koc University, Istanbul (Turkey)
- Bahcesehir University, Istanbul (Turkey)
- Bahcesehir University, Istanbul (Turkey); Gebze Technical University, Kocaeli (Turkey)
- Bahcesehir University, Istanbul (Turkey); Istanbul Technical University (Turkey)
- Bahcesehir University, Istanbul (Turkey); Mersin University (Turkey)
- Deutsches Elektronen-Synchrotron (DESY), Hamburg (Germany)
- Arizona State Univ., Tempe, AZ (United States)
- SLAC National Accelerator Lab., Menlo Park, CA (United States). Photon Ultrafast Laser Science and Engineering Inst. (PULSE)
- SLAC National Accelerator Lab., Menlo Park, CA (United States). Linac Coherent Light Source (LCLS)
- SLAC National Accelerator Lab., Menlo Park, CA (United States). Linac Coherent Light Source (LCLS); Stanford Univ., CA (United States)
- State Univ. of New York at Buffalo, NY (United States)
- Koc University, Istanbul (Turkey); SLAC National Accelerator Lab., Menlo Park, CA (United States). Photon Ultrafast Laser Science and Engineering Inst. (PULSE)
The COVID-19 pandemic has resulted in 198 million reported infections and more than 4 million deaths as of July 2021 (covid19.who.int). Research to identify effective therapies for COVID-19 includes: (1) designing a vaccine as future protection; (2) de novo drug discovery; and (3) identifying existing drugs to repurpose them as effective and immediate treatments. To assist in drug repurposing and design, we determine two apo structures of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease at ambient temperature by serial femtosecond X-ray crystallography. We employ detailed molecular simulations of selected known main protease inhibitors with the structures and compare binding modes and energies. The combined structural and molecular modeling studies not only reveal the dynamics of small molecules targeting the main protease but also provide invaluable opportunities for drug repurposing and structure-based drug design strategies against SARS-CoV-2.
- Research Organization:
- SLAC National Accelerator Laboratory (SLAC), Menlo Park, CA (United States)
- Sponsoring Organization:
- Bahcesehir University (BAU) Scientific Research Projects (BAP); National Science Foundation (NSF); Scientific and Technological Research Council of Turkey (TUBITAK); USDOE Office of Science (SC), Basic Energy Sciences (BES). Chemical Sciences, Geosciences & Biosciences Division
- Grant/Contract Number:
- AC02-76SF00515
- OSTI ID:
- 1819309
- Report Number(s):
- SLAC-PUB--17616
- Journal Information:
- Structure, Journal Name: Structure Journal Issue: 12 Vol. 29; ISSN 0969-2126
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment
Probing the SARS-CoV-2 main protease active site as a target to inhibit viral replication
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
Journal Article
·
Thu Nov 23 19:00:00 EST 2023
· Experimental Biology and Medicine
·
OSTI ID:2582848
Probing the SARS-CoV-2 main protease active site as a target to inhibit viral replication
Journal Article
·
Thu Feb 25 23:00:00 EST 2021
· Research Features
·
OSTI ID:1770639
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
Journal Article
·
Wed Aug 26 20:00:00 EDT 2020
· Nature Communications
·
OSTI ID:1816374